Eukaryotic expression plasmids encoding either the avian influenza hemagglutinin or matrix genes (pCMV-HA and pCMV-M, respectively) were constructed. The viral genes were derived from a low-pathogenicity H7N1 strain, A/Chicken/Italy/1067/99, isolated during the 1999–2001 epizootic in Italy. The plasmid was administered to 4-to-5-wk-old specific-pathogen-free chickens by several different injection methods. For the initial studies comparing methods of vaccine injection, results were compared based on hemagglutination inhibition (HI) response following immunization with pCMV-HA. Additional studies with coadministration of both pCMV-HA and pCMV-M was evaluated based on HI response and viral isolation after homologous challenge. Preliminary results indicate that a device intended to inject insulin in humans (Medijector) and the coadministration of both plasmids improved protection against H7 infection.
How to translate text using browser tools
1 September 2003
Strategies to Improve Protection Against Low-Pathogenicity H7 Avian Influenza Virus Infection Using DNA Vaccines
M. Cherbonnel,
J. Rousset,
V. Jestin
ACCESS THE FULL ARTICLE
avian influenza
DNA vaccines
H7
hemagglutinin
low pathogenicity
matrix protein